Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	7/11/2001 12:44:25 PM
From: nigel bates	of 469

From Saskia Wirth's (FTMarketWatch.com) report on the H&Q 9th Annual Investing in Biotechnology Conference in London - UK biotech company Oxford GlycoSciences [UK:OGS] said it was on target to file this year for regulatory approval in the U.S. and Europe for its Gaucher disease drug Vevesca. Vevesca is expected to be a key driver of growth and revenues for the company, which added that it is set to release further data on the drug from September. OGS also said it was on target to file patents for 4,000 disease-associated proteins in 2001, while it stressed the company remained in a very strong financial position with £203 million in cash to fall back on to fund its operations... (edit) I think they had 1500 last time they mentioned a number...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next